Moxonidine Effects on Neuropeptide Y

Effects of Moxonidine Administration on Serum Neuropeptide Y Levels in Hypertensive Individuals: A Prospective Observational Study

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05147753

Enrollment

Registered

2021-12-07

Start date

2010-01-11

Completion date

2014-06-30

Last updated

2021-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Obesity

Keywords

hypertension, obesity, Neuropeptide Y, moxonidine

Brief summary

Treatment with monotherapy of moxonidine 0.6 mg daily in treatment-naïve subjects with mild or moderate hypertension

Detailed description

Treatment with 0.6 mg moxonidine daily in treatment-naïve subjects with mild or moderate hypertension according to guidelines (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: systolic blood pressure=160-179 mmHg, diastolic blood pressure=100-109 mmHg) that require monotherapy and reevaluation after 12 weeks

Interventions

DRUGMoxonidine

0.6 mg moxonidine daily

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to 75 Years

Healthy volunteers

Inclusion criteria

* treatment-naïve subjects with mild or moderate hypertension according to Joint National Committee 7 and European Society Hypertension / European Society Cardiology 2008 (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: Systolic=160-179 mmHg, Diastolic=100-109 mmHg) that require monotherapy

Exclusion criteria

* age beyond 25-75 years, * not taking currently anti-hypertensive medication * not taking anti-diabetic or lipid lowering medication and other diseases or conditions that may influence blood pressure, heart rate and catecholamines' and Neuropeptide Y levels, including anemia, fever, stage III hypertension, coronary artery disease, recent (less than 6 months) myocardial infraction or stroke, heart failure, secondary hypertension, diabetes mellitus, abnormal thyroid status or other obesity-related endocrinopathies, pregnancy, kidney failure, alcohol abuse, malignancies, depression or other psychiatric illnesses, such as schizophrenia,

Design outcomes

Primary

Measure	Time frame	Description
serum Neuropeptide Y levels	12 weeks	ELISA
systolic blood pressure	12 weeks	mmHg
diastolic blood pressure	12 weeks	mmHg

Secondary

Measure	Time frame	Description
HDL Cholesterol	12 weeks	mg/dl
Weight	12 weeks	kg
Serum triglycerides	12 weeks	mg/dl
LDL Cholesterol	12 weeks	mg/dl
Body Mass Index	12 weeks	kg/m2
Total Cholesterol	12 weeks	mg/dl

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026